Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
The collaboration will support Canada with direct access to rapid pandemic response capabilities
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
If approved it will bring a second source of MMR vaccine to the US market
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
This work has been published in the journal ‘ACS applied materials and interface’
Subscribe To Our Newsletter & Stay Updated
